aspirin and bl 4162a

aspirin has been researched along with bl 4162a in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (2.44)	18.7374
1990's	4 (9.76)	18.2507
2000's	20 (48.78)	29.6817
2010's	14 (34.15)	24.3611
2020's	2 (4.88)	2.80

Authors

Authors	Studies
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chintagumpala, MM; Fernbach, DJ; Mahoney, DH; Ogden, AK; Steuber, CP	1
Clark, WF; Moriarity, TA; Reid, BD; Tevaarwerk, GJ	1
Mughal, TI	1
Silverstein, MN; Tefferi, A	1
Green, AR	1
Briere, J; Guilmin, F	1
Bangerter, M; Griesshammer, M; Grünewald, M	1
Tefferi, A; Wright, CA	1
Solberg, LA	1
Griesshammer, M; Langer, C	1
Schafer, AI	1
Putti, MC; Randi, ML	1
Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE	1
Barbui, T; Finazzi, G	2
Costello, R; O'Callaghan, T; Sébahoun, G	1
Petrides, PE	2
Gisslinger, H	1
Reilly, JT	1
Bareford, D; Buck, G; Campbell, PJ; East, CL; Erber, WN; Green, AR; Harrison, CN; Paul, B; Wheatley, K; Wilkins, BS	1
Cacciola, E; Cacciola, RR; Di Francesco, E; Giustolisi, R; Pezzella, F; Tibullo, D	1
Birgegård, G	1
Beer, PA; Green, AR	1
Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB	1
Vannucchi, AM	1
Dowson, A; Frewin, R	1
Alvarez-Larrán, A; Besses, C; Cervantes, F	1
Haznedaroglu, IC	1
Balasubramaniam, K; Dragone, J; Grose-Hodge, R; Martin, P; Preston, P; Troy, S; Viswanathan, G; Zaman, AG	1
Miyamoto, T; Yoshimoto, G	1
Brychtová, Y; Campr, V; Černá, O; Červinek, L; Cmunt, E; Doubek, M; Dulíček, P; Kissová, J; Křen, L; Maaloufová Soukupová, J; Ovesná, P; Penka, M; Schwarz, J	1
Hoffman, R; Kremyanskaya, M; Mascarenhas, J	1
Fujimura, K; Shimazu, Y	1
Demeter, J; Dombi, P; Egyed, M; Homor, L; Illés, Á; Karadi, E; Simon, Z; Udvardy, M	1
Corvetta, D; Di Pierro, AM; Eakins, E; Feistritzer, C; Gambato, R; Gastl, G; Gherlinzoni, F; Gottardi, M; Krampera, M; Langes, M; Marcheselli, L; Mazzoleni, G; Mega, A; Murphy, C; Pacquola, E; Perbellini, O; Piccin, A; Piva, E; Plebani, M; Pusceddu, I; Steurer, M; Tauber, M; Van Schilfgaarde, M; Veneri, D	1
Usui, N	1
Arimura, A; Fujii, K; Hashiguchi, T; Hayashida, M; Higashi, Y; Kanekura, T	1
Demeter, J; Dombi, P; Egyed, M; Ercsei, I; Gasztonyi, Z; Gy Korom, V; Herczeg, J; Homor, L; Illes, A; Karadi, E; Kellner, A; Simon, Z; Szerafin, L; Udvardy, M	1

Reviews

22 review(s) available for aspirin and bl 4162a

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Primary thrombocythemia: a current perspective. Stem cells (Dayton, Ohio), 1995, Volume: 13, Issue:4 Topics: Aspirin; Diagnosis, Differential; Humans; Hydroxyurea; Interferon Type I; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Recombinant Proteins; Thrombocytosis	1995
Treatment of polycythaemia vera and essential thrombocythaemia. Bailliere's clinical haematology, 1998, Volume: 11, Issue:4 Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis	1998
The pathogenesis and management of essential thrombocythaemia. Haematologica, 1999, Volume: 84 Suppl EHA-4 Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia	1999
Management of patients with essential thrombocythemia: current concepts and perspectives. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Progression; Female; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Quinazolines; Risk; Safety; Thrombocythemia, Essential; Thrombophilia	2001
Current treatment practice for essential thrombocythaemia in adults. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3 Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thrombocythemia, Essential	2001
A single institutional experience with 43 pregnancies in essential thrombocythemia. European journal of haematology, 2001, Volume: 66, Issue:3 Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulfan; Erythromelalgia; Female; Fetal Death; Follow-Up Studies; Heparin; Humans; Hydroxyurea; Migraine Disorders; Obstetric Labor, Premature; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Platelet Count; Plateletpheresis; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy, Ectopic; Pregnancy, High-Risk; Quinazolines; Retrospective Studies; Risk; Thrombocythemia, Essential; Uterine Hemorrhage	2001
Therapeutic options for essential thrombocythemia and polycythemia vera. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Busulfan; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Phosphorus Radioisotopes; Polycythemia Vera; Quinazolines; Risk Assessment; Thrombocytosis	2002
Pharmacotherapy of essential thrombocythaemia: economic considerations. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9 Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Quinazolines; Risk Factors; Thrombocythemia, Essential	2003
Thrombocytosis. The New England journal of medicine, 2004, Mar-18, Volume: 350, Issue:12 Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2004
[Treatment of essential thrombocythemia]. La Revue de medecine interne, 2005, Volume: 26, Issue:12 Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Thrombocythemia, Essential	2005
Anagrelide: what was new in 2004 and 2005? Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; History, 21st Century; Humans; Hydroxyurea; Male; Megakaryocytes; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Thrombocythemia, Essential	2006
Update on diagnosis and management of essential thrombocythemia. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Life Expectancy; Male; Quinazolines; Risk Factors; Thrombocythemia, Essential	2006
[Primary thrombocythemia: diagnosis and therapy]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Male; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Primary Prevention; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocythemia, Essential; Time Factors	2006
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia, 2008, Volume: 22, Issue:8 Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia Vera; Quinazolines; Risk Factors; Survival Analysis; Thrombocythemia, Essential	2008
Long-term management of thrombocytosis in essential thrombocythaemia. Annals of hematology, 2009, Volume: 88, Issue:1 Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pregnancy; PubMed; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombocytosis	2009
Pathogenesis and management of essential thrombocythemia. Hematology. American Society of Hematology. Education Program, 2009 Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia	2009
JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Current hematologic malignancy reports, 2010, Volume: 5, Issue:1 Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Incidence; Interferon-alpha; Janus Kinase 2; Multicenter Studies as Topic; Mutation, Missense; Myeloproliferative Disorders; Phenotype; Point Mutation; Quinazolines; Thrombophilia; Thrombosis	2010
Headache in essential thrombocythaemia. International journal of clinical practice, 2012, Volume: 66, Issue:10 Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Headache Disorders; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals; Risk Factors; Thrombocythemia, Essential	2012
[Treatment of essential thrombocythemia]. Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6 Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia	2013
[Treatment strategy for myeloproliferative neoplasms]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential	2014
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8 Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Polyethylene Glycols; Pyrazoles; Pyrimidines; Quinazolines	2015

Trials

4 trial(s) available for aspirin and bl 4162a

Article	Year
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombosis	2005
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 2008, Jan-01, Volume: 111, Issue:1 Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematology; Humans; Hydroxyurea; Megakaryocytes; Observer Variation; Pathology, Clinical; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocytosis	2008
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Hydroxyurea; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Factor 4; Prothrombin; Quinazolines; Thrombocythemia, Essential; Thrombosis	2007
Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Adult; Aspirin; Blood Coagulation; Blood Platelets; Cross-Over Studies; Drug Therapy, Combination; Headache; Humans; Imidazoles; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombelastography; Thrombocytopenia; Thrombosis	2014

Other Studies

15 other study(ies) available for aspirin and bl 4162a

Article	Year
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, 2011, Volume: 46, Issue:1 Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics	2011
Essential thrombocythemia in a child: management with anagrelide. The American journal of pediatric hematology/oncology, 1991,Spring, Volume: 13, Issue:1 Topics: Aspirin; Child; Drug Therapy, Combination; Humans; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential	1991
Inhibitors of immune complex induced human platelet aggregation and release in plasma. Thrombosis research, 1982, Dec-01, Volume: 28, Issue:5 Topics: Antibodies; Antigen-Antibody Complex; Aspirin; Blood Platelets; Depression, Chemical; Dipyridamole; DNA; Humans; Imidazoles; Indomethacin; Lupus Erythematosus, Systemic; Male; Platelet Aggregation; Quinazolines; Receptors, Fc; Sulfinpyrazone	1982
Essential thrombocythaemia in children: is a treatment needed? Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5 Topics: Adult; Aspirin; Child; Clinical Trials, Phase II as Topic; Humans; Interferon-alpha; Quinazolines; Thrombocythemia, Essential	2004
When and how to treat essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2005
Practical approach to treating essential thrombocythaemia: case studies. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; Middle Aged; Pipobroman; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Warfarin	2007
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythropoietin; Fatal Outcome; Female; Humans; Hydroxyurea; Jehovah's Witnesses; Kidney Failure, Chronic; Kidney Function Tests; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Renal Dialysis; Thrombocythemia, Essential	2009
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:11 Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment; Thrombocythemia, Essential	2013
Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. European journal of haematology, 2016, Volume: 96, Issue:1 Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Aspirin; Female; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Male; Mutation, Missense; Philadelphia Chromosome; Platelet Count; Prospective Studies; Quinazolines; Registries; Risk Factors; Thrombocytosis; Thrombosis	2016
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Pancreatitis; Phosphodiesterase Inhibitors; Quinazolines; Thrombocythemia, Essential	2016
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. European journal of haematology, 2017, Volume: 98, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hungary; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombosis	2017
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Translational research : the journal of laboratory and clinical medicine, 2017, Volume: 184 Topics: Adrenomedullin; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell-Derived Microparticles; Endothelin-1; Endothelium, Vascular; Female; Humans; Hydroxyurea; Male; Middle Aged; Nitric Oxide; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2017
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). International journal of hematology, 2017, Volume: 106, Issue:5 Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk	2017
Anagrelide with low-dose aspirin promptly epithelized ulceronecrotic lesion secondary to essential thrombocythemia. The Journal of dermatology, 2020, Volume: 47, Issue:5 Topics: Aspirin; Bone Marrow; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinase 2; Karyotyping; Male; Middle Aged; Mutation; Necrosis; Quinazolines; Re-Epithelialization; Skin; Skin Ulcer; Thrombocythemia, Essential; Toes; Treatment Outcome	2020
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. European journal of haematology, 2020, Volume: 105, Issue:4 Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis; Treatment Outcome	2020